As legislators review the Biotech Act, they face a generational opportunity to strengthen Europe’s clinical trials landscape and its global competitiveness.
The Commission’s proposal outlines changes that can help reverse Europe’s declining share in global clinical research, bridge the emerging competitiveness gap, and enable a faster, patient-center and more ambitious approach to clinical trials, while maintaining the EU regulatory standards.
Bringing together policymakers and stakeholders, this discussion will examine how the proposal can deliver on these ambitions and identify key elements ahead of upcoming negotiations. It will also explore perspectives from EU Member States that are leading in clinical trials.
This event is by invitation only.
